Evidence map›Paper›PMID 36982482›Full record

ArticleInternational journal of molecular sciences2023

Piergiuseppe De Rosa, Federica Severi, Suleman Khan Zadran, Marco Russo, Sara Aloisi, Alberto Rigamonti, Giovanni Capranico, Giorgio Milazzo, Giovanni Perini

Open access · goldFull text read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 6 citations in OpenAlex.

  1. Comparative Functional Effects of Abemaciclib and Arcyriaflavin A inInternational journal of molecular sciences · 2026
    Article
  2. Article
  3. Targeted therapies in pediatric oncology: A start.Molecular therapy. Oncology · 2026
    Review
  4. Article
  5. Review
  6. Article
  7. Novel Therapeutic Targets in Cancers.International journal of molecular sciences · 2023
    Article
  8. Detection of Tumor Suppressor Genes Rare Variants: Findings From Neuroblastoma Using Next-Generation Sequencing.Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Piergiuseppe De RosaDepartment of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.ORCID 0000-0002-2632-1473
Federica SeveriDepartment of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.ORCID 0000-0002-7269-0958
Suleman Khan ZadranDepartment of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.ORCID 0000-0002-7138-0720
Marco RussoDepartment of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.ORCID 0000-0002-0550-0608
Sara AloisiDepartment of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.ORCID 0000-0002-1791-228X
Alberto RigamontiDepartment of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.
Giovanni CapranicoDepartment of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.ORCID 0000-0002-8708-6454
Giorgio MilazzoDepartment of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.ORCID 0000-0002-1930-4763
Giovanni PeriniDepartment of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy.ORCID 0000-0002-0150-8477
University of Bologna · IT

Funding

Italian Association for Cancer Research AIRC2020-IG24341
6 · The paper itself

Abstract

Neuroblastoma (NB) is one of the primary causes of death for pediatric malignancies. Given the high heterogeneity in NB's mutation landscape, optimizing individualized therapies is still challenging. In the context of genomic alterations,

Indexed as

NeuroblastomaCell CycleCell Line, TumorCell ProliferationChildCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6Gene AmplificationGene Expression Regulation, NeoplasticHumansN-Myc Proto-Oncogene ProteinRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6MYCN protein, humanN-Myc Proto-Oncogene ProteinRB1 protein, humanRetinoblastoma Binding ProteinsUbiquitin-Protein LigasesCRISPRiE2FMYCNNeuroblastomapalbociclibRBribociclibΔCDK

Identifiers

PMID36982482
PMCPMC10049239
OpenAlexW4324097038

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read38
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.